Evidence map›Paper›PMID 25750158›Full record

ArticleJournal of cancer survivorship : research and practice2015

Hormonal dysfunction is frequent in cancer survivors treated with radiotherapy to the head and neck region.

Mette Seland, Trine Bjøro, Torbjørn Furre, Thomas Schreiner, Jens Bollerslev, Sophie Dorothea Fosså, Jon Håvard Loge, Harald Holte, Cecilie Essholt Kiserud

Abstract read
PubMed Publisher
In one paragraph

Article in Journal of cancer survivorship : research and practice, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Trial
  3. Review
  4. Article
  5. Article
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Mette SelandOslo University Hospital, Oslo, Norway. metse@ous-hf.no.
Trine BjøroOslo University Hospital, Oslo, Norway.
Torbjørn FurreOslo University Hospital, Oslo, Norway.
Thomas SchreinerOslo University Hospital, Oslo, Norway.
Jens BollerslevOslo University Hospital, Oslo, Norway.
Sophie Dorothea FossåOslo University Hospital, Oslo, Norway.
Jon Håvard LogeOslo University Hospital, Oslo, Norway.
Harald HolteOslo University Hospital, Oslo, Norway.
Cecilie Essholt KiserudOslo University Hospital, Oslo, Norway.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeCancer treatment may lead to hormonal dysfunction. Therefore, we assessed the prevalence of dysfunction in four hormonal axes among long-term cancer survivors who received radiotherapy to the head and neck region and analyzed associations between hormonal status and clinical variables.

methodsWe included 140 cancer survivors who received radiotherapy to the head and neck region, either locally or through total body irradiation after a diagnosis of lymphoma, plasmacytoma/multiple myeloma, or carcinoma of the epipharynx. Radiation doses to the pituitary gland and thyroid gland were estimated, and blood samples were collected to analyze hormonal levels.

resultsAt a median of 16 years after their cancer diagnosis, 46% of cancer survivors showed dysfunction in one hormonal axis, 24% had dysfunction in two axes, and 3% had dysfunction in three axes. Twenty cancer survivors (14%) had hormone levels consistent with pituitary dysfunction. Cancer survivors who had received an estimated 30 Gray (Gy) or more to the pituitary gland had an increased risk for pituitary dysfunction in one of the hormonal axes (odds ratio [OR] 3.16, confidence interval [CI] 1.02-9.87, p = 0.047) and for growth hormone dysfunction alone (OR 2.96, CI 1.02-8.55, p = 0.045).

conclusionsAbnormal hormone values are frequent after radiotherapy to the head and neck region. IMPLICATIONS FOR CANCER SURVIVORS: Screening for hormonal dysfunction during follow-up might be indicated.

Indexed as

AdolescentAdultAgedAged, 80 and overCross-Sectional StudiesEndocrine System DiseasesFemaleHead and Neck NeoplasmsHumansMaleMiddle AgedPituitary GlandPrevalenceRadiation InjuriesRadiotherapy DosageSurvivorsCancerHormonal dysfunctionLate effectsRadiotherapy

Identifiers

PMID25750158

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.